Skip to main content
. 2016 Dec 16;8(6):9251–9266. doi: 10.18632/oncotarget.14002

Figure 6. ERK-mediated mechanism of resistance to LY3009120.

Figure 6

(A) HCT 116 parental (blue line) and HCT 116 LY3009120-resistant cells (red line) were generated and assessed for their sensitivity to various kinase inhibitors of the MAPK signaling cascade. LY3009120: panRAF inhibitor (top panel); trametinib: MEK1/2 inhibitor (middle panel); ERKi: VX-11e ERK2 inhibitor (lower panel). (B) RAS-GTP levels were analyzed from cell lysates of LY3009120-sensitive and LY3009120-resistant HCT 116 by an active-RAS pulldown assay as delineated in the experimental procedures. Whole cell lysates were also analyzed by Western blot using antibodies against the proteins indicated. (C) Whole cell lysates of LY3009120-sensitive and LY3009120-resistant HCT 116 were analyzed by Western blot for baseline pathway activation using antibodies against the proteins indicated.